These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2997976)

  • 61. Evaluation of the humoral immune response induced by vaccination for canine distemper and parvovirus: a pilot study.
    Vila Nova B; Cunha E; Sepúlveda N; Oliveira M; São Braz B; Tavares L; Almeida V; Gil S
    BMC Vet Res; 2018 Nov; 14(1):348. PubMed ID: 30445957
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Canine parvovirus: interaction between passive immunity and virulent challenge.
    Macartney L; Thompson H; McCandlish IA; Cornwell HJ
    Vet Rec; 1988 Jun; 122(24):573-6. PubMed ID: 2842925
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
    Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vaccination at different anatomic sites induces different levels of the immune responses.
    Jin H; Xu Y; Shi F; Hu S
    Res Vet Sci; 2019 Feb; 122():50-55. PubMed ID: 30453180
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Canine parvovirus infection in dogs: a consideration].
    Rimmelzwaan GF; Uytdenhaag FG; Osterhaus AD
    Tijdschr Diergeneeskd; 1986 Sep; 111(18):847-59. PubMed ID: 3020734
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
    Siedek EM; Schmidt H; Sture GH; Raue R
    Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus.
    Lakshmanan N; Gore TC; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2006; 7(3):223-31. PubMed ID: 17039445
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evolution of canine parvovirus--a need for new vaccines?
    Truyen U
    Vet Microbiol; 2006 Oct; 117(1):9-13. PubMed ID: 16765539
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adjuvant properties of killed Propionibacterium avidum KP-40 in vaccination of dogs against canine parvovirosis.
    Siwicki AK; Krzyzanowski J; Bartoszcze M; Mizak Z; Paluch S; Szmigielski S; Jeljaszewicz J; Pulverer G
    Dtsch Tierarztl Wochenschr; 1998 May; 105(5):186-90. PubMed ID: 9646552
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibody levels and protection to canine parvovirus type 2.
    Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Canine parvovirus in vaccinated dogs: a field study.
    Miranda C; Thompson G
    Vet Rec; 2016 Apr; 178(16):397. PubMed ID: 26960988
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Frequency of CPV infection in vaccinated puppies that attended puppy socialization classes.
    Stepita ME; Bain MJ; Kass PH
    J Am Anim Hosp Assoc; 2013; 49(2):95-100. PubMed ID: 23325595
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines.
    Bergman JG; Muniz M; Sutton D; Fensome R; Ling F; Paul G
    Vet Rec; 2006 Nov; 159(22):733-6. PubMed ID: 17127756
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
    Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
    New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Are we becoming unaffordable to owners?
    Taylor N
    Vet Rec; 2020 Sep; 187(6):243. PubMed ID: 32948731
    [No Abstract]   [Full Text] [Related]  

  • 76. Application of a dot enzyme-linked immunosorbent assay for evaluation of the immune status to canine parvovirus and distemper virus in adult dogs before revaccination.
    Waner T; Mazar S; Keren-Kornblatt E
    J Vet Diagn Invest; 2006 May; 18(3):267-70. PubMed ID: 16789715
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of isolates of canine parvovirus by restriction enzyme analysis, and vaccine efficacy against field strains.
    Greenwood NM; Chalmers WS; Baxendale W; Thompson H
    Vet Rec; 1995 Jan; 136(3):63-7. PubMed ID: 7725611
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of a dot ELISA kit for measuring immunoglobulin M antibodies to canine parvovirus and distemper virus.
    Waner T; Mazar S; Nachmias E; Keren-Kornblatt E; Harrus S
    Vet Rec; 2003 May; 152(19):588-91. PubMed ID: 12762487
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk factors associated with parvovirus enteritis in dogs: 283 cases (1982-1991).
    Houston DM; Ribble CS; Head LL
    J Am Vet Med Assoc; 1996 Feb; 208(4):542-6. PubMed ID: 8603904
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular typing of canine parvovirus strains circulating from 2008 to 2012 in an organized kennel in India reveals the possibility of vaccination failure.
    Mittal M; Chakravarti S; Mohapatra JK; Chug PK; Dubey R; Upmanuyu V; Narwal PS; Kumar A; Churamani CP; Kanwar NS
    Infect Genet Evol; 2014 Apr; 23():1-6. PubMed ID: 24486948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.